Heather Harle, MD
Neurology · Lancaster, PANPI 1992919138
Payments from drug & device makers
Across 168 payments — averaging $25.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$915
- Novartis$350
- Biogen$300
- UCB, Inc.$292
- EMD Serono, Inc.$232
- AstraZeneca$212
- plus $2K from 28 others
What the payments were for
- Speaking & faculty fees$291%
- Food & beverage$4,05595%
- Education$1945%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 69 | $915 |
| Novartis | 15 | $350 |
| Biogen | 11 | $300 |
| UCB, Inc. | 4 | $292 |
| EMD Serono, Inc. | 11 | $232 |
| AstraZeneca | 4 | $212 |
| Lundbeck LLC | 4 | $195 |
| E.r. Squibb & Sons, L.L.C. | 3 | $167 |
| SK Life Science, Inc. | 4 | $154 |
| MDD US Operations, LLC | 6 | $148 |
| Amgen | 2 | $139 |
| Medtronic(2 entities) | 2 | $138 |
| Alnylam Pharmaceuticals Inc. | 1 | $125 |
| Jazz Pharmaceuticals Inc. | 1 | $125 |
| Neurocrine Biosciences, Inc. | 2 | $123 |
| Argenx US, Inc. | 4 | $112 |
| Impel Pharmaceuticals Inc. | 1 | $74 |
| Bristol Myers Squibb | 3 | $53 |
| Amneal Pharmaceuticals LLC | 3 | $51 |
| CSL Behring | 1 | $50 |
| Pfizer | 2 | $46 |
| TG Therapeutics, Inc. | 2 | $45 |
| Genentech USA, Inc. | 2 | $31 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $29 |
| Impel Pharmaceuticals LLC | 1 | $27 |
| Acorda Therapeutics, Inc | 1 | $24 |
| Lilly USA, LLC | 1 | $21 |
| Acadia Pharmaceuticals Inc | 1 | $19 |
| Merz Pharmaceuticals, LLC | 1 | $18 |
| Neurelis, Inc. | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Livanova USA, Inc. | 1 | $16 |
| Zyla Life Sciences, Inc. | 1 | $11 |
| Supernus Pharmaceuticals, Inc. | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,278 in reported general payments places this provider in the 65th percentile of 941 neurology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 22 | $218,865 |
| Kesimpta PenOfatumumab | 18 | $152,375 |
| Emgality PenGalcanezumab-Gnlm | 176 | $138,845 |
| XcopriCenobamate | 53 | $69,598 |
| Nurtec OdtRimegepant Sulfate | 50 | $65,701 |
| Aimovig AutoinjectorErenumab-Aooe | 74 | $63,847 |
| Dimethyl Fumarate | 26 | $42,615 |
| EliquisApixaban | 35 | $37,166 |
| BotoxOnabotulinumtoxina | 29 | $35,210 |
| QuliptaAtogepant | 29 | $30,186 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 34 | $26,262 |
| FingolimodFingolimod Hcl | 12 | $23,555 |
| RytaryCarbidopa/Levodopa | 12 | $22,249 |
| OnfiClobazam | 11 | $19,309 |
| UbrelvyUbrogepant | 19 | $17,088 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt, Eliquis, Dilantin | $46 | $106,710101 claims |
| AbbVieBotox, Qulipta, Ubrelvy | $915 | $82,48477 claims |
| SK Life Science, Inc.Xcopri | $154 | $69,59853 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide, Mycophenolate Mofetil | $51 | $31,345106 claims |
| Lundbeck LLCOnfi | $195 | $19,30911 claims |
| UCB, Inc.Nayzilam | $292 | $8,67811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 941 neurology providers in Pennsylvania.
Other neurology in Lancaster
- David WeismanAbington$9.3M
- Amit Bar-OrPhiladelphia$7.7M
- Thomas LeistPhiladelphia$5.8M
- Jan DrappatzPittsburgh$4M
- Lauren ElmanPhiladelphia$3.3M
- David IrwinPhiladelphia$2.5M
- Paula ClemensPittsburgh$2.1M
- Anoopum GuptaPittsburgh$2M
- Daniel KremensPhiladelphia$1.9M
- Frances JensenPhiladelphia$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.